HER2 Inhibitor Resistance Diagnostic Kit Using Gene Expression Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers and diagnostic kits for determining HER2 inhibitor resistance in cancer patients lack reliability, leading to overtreatment and increased medical expenses due to the prescription of unnecessary drugs, as there is no commercially available product that effectively assesses resistance to HER2 inhibitors like Herceptin.
Innovation Solution
A diagnostic marker and kit that measure the expression levels of specific genes associated with HER2 inhibitor resistance, such as ATF4, CHEK2, EGF, EGLN2, ENAH, FARP2, and RAD51, using mRNA or protein expression analysis to determine resistance, thereby allowing for the prescription of second-line drugs and minimizing side effects and costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current biomarkers and diagnostic kits are used to determine HER2 inhibitor resistance, then diagnosis can be performed, but the reliability of resistance determination is low leading to overtreatment
Solution Approach 1:
The patent changes the diagnostic parameters by identifying and measuring specific genes (ATF4, CHEK2, EGF, EGLN2, ENAH, FARP2, RAD51) whose expression levels correlate with HER2 inhibitor resistance. This parameter change enables reliable resistance determination through quantifying mRNA or protein expression of these specific genes, thereby resolving the contradiction between reliability and product availability.
2Productivity
If HER2 inhibitors are prescribed to all HER2-positive cancer patients, then treatment coverage is maximized, but unnecessary drugs are prescribed leading to increased medical expenses and side effects
Solution Approach 1:
The patent applies preliminary action by performing resistance determination diagnosis before prescribing HER2 inhibitors. By measuring the expression levels of resistance-related genes (ATF4, CHEK2, EGF, EGLN2, ENAH, FARP2, RAD51) in advance, the system identifies patients who will respond to treatment versus those who will not, preventing unnecessary drug administration and its associated side effects and costs.
3Ease of operation
If first-line drug therapy is prescribed to all cancer patients, then standard treatment protocol is followed, but alternative therapy is required when patients do not respond
Solution Approach 1:
The patent performs preliminary resistance determination before initiating first-line HER2 inhibitor therapy by measuring gene expression levels of resistance markers (ATF4, CHEK2, EGF, EGLN2, ENAH, FARP2, RAD51). This preliminary action identifies suitable candidates for HER2 inhibitor treatment, ensuring that patients who will not respond are identified beforehand, thus avoiding time loss from ineffective treatment and enabling timely alternative therapy selection.
Data Source
AI summary
The present invention relates to a composition for detecting a marker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker. More particularly, the present invention relates to a composition for detecting a maker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker, wherein the present invention allows presence and absence of resistance to an HER2 inhibitor, which is typically prescribed to an HER2-positive cancer patient, in an HER2-positive cancer patient to be determined in an easier manner with remarkably high reliability.